HRT can also be a concern after treatment. If you’ve been treated for HR+ breast cancer, “There is always some small risk ...

To evaluate the clinical benefit of extended endocrine therapy after 5 years of adjuvant treatment with LHRHa in premenopausal women with node-positive, HR-positive early breast cancer.

Men with prostate cancer who get hormone therapy experience hot flashes, where they experience intense and sudden heat and ...

Breast cancer risk is a central concern in shared decision-making when considering menopausal hormone treatment (MHT). Women spend approximately 40% of their lives in menopause, and climacteric ...

More than 40% of Americans with estrogen receptor (ER)-low early breast cancer did not receive endocrine therapy, analysis of a national database showed. Omitting endocrine therapy in ER-low breast ...

Up to 20% of hormone receptor-positive breast cancers don't respond to antiestrogen therapies. A study led by researchers at ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

Verzenio plus endocrine therapy reduced death risk by 15.8% in high-risk early breast cancer patients compared to endocrine therapy alone. The monarchE trial showed improved OS and IDFS rates with ...

In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen receptor antagonist and degrader (SERD), when given as an adjuvant therapy ...

Retrospective Study to Determine Factors Influencing Outcome in Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Receiving Neoadjuvant Chemotherapy Women with ...

More than 46% of women with stage 1 or 2 breast cancer chose to continue endocrine therapy after five years, a recent study found. The study, published in the Journal of the National Cancer Institute, ...

A new study found that a combination of hormone therapy and the GLP-1 medication tirzepatide (Zepbound) led to 35% more ...